secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2024-04-05T23:59:59+00:00
Accession:  0000950170-24-042057
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics reports positive 48-week FOREST-HCM data on aficamten at ACC
-------------------------------------------------------------------------

- 46 patients completed 48 weeks; 75% on 15mg or 20mg dose of aficamten.
- Mean resting LVOT-G reduced by 39.6 mmHg (p<0.0001) and Valsalva LVOT-G by 53.2 mmHg.
- 82.2% improved by ≥1 NYHA class; no worsening class observed.
- NT-proBNP decreased 63% (p<0.001); SRT-eligibility reduced 94%.
- No treatment-related SAEs; modest LVEF reduction (-5.1%) with three dose adjustments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024042057/0000950170-24-042057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024042057/cytk-20240405.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-042057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer